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SUMMARY
It has been well demonstrated the relationship between the infection with high-risk human papillomavirus (HPVs) genotypes and
cervical cancer. In Northeastern Argentina a high incidence of this pathology has been described and therefore a high prevalence of
HPV infection is expected. In order to identify HPV genotypes associated with malignant and pre-malignant cervical lesions present
in the area, 53 ecto-endo cervical cell specimens obtained from women with cytohistological alterations were studied by a PCR-RFLP
technique. Out of 53 patients, 34 (64.2%) were positive for HPV infection, being HPV-16 (32.3%) the most frequently found genotype,
followed by HPV-58 (14.7%), -6, -18 and –45 (5.9%), -33, -52, -53, -54, -56, -66, -MM4 and –LVX100 (2.9%). Also 5 cases of
infection caused by multiple genotypes were found, which corresponded to 14.7% of the positive cases. Results indicate that besides
HPV-16 and –18, the most prevalent high-risk HPV genotypes worldwide, others like –45 and –58 as well as co-infection cases are
frequent between women of Northeastern Argentina, and a particular attention should be paid to this circumstance because it could be
an epidemiological feature of regional importance and a useful information for a future vaccination program.
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INTRODUCTION
Human papillomavirus (HPVs) are natural occurring DNA tumor
viruses which induce epithelial proliferation during the course of a
productive infection and are known to be consistently associated with
cervical cancer18,31.
Human papillomavirus invade epithelium germinal cells through
microlesions and the resulting infection may be transient or
persistent4,10,27.
Even though infection with oncogenic HPV genotypes is frequent
among sexually active women, most of the cases are autolimited28; the
development of malignant cervical lesions only occurs in a small
proportion of infected women that harbor persistent infections with
oncogenic genotypes9,17,26. It has been demonstrated the integration of
viral genome within malignant cells in all cervical cancer cases, which
is thought to be a necessary condition for the development of
neoplasia11,12,21.
More than 80 HPV genotypes have been identified up to the present
days, and about 40 of them infect the anogenital region. Within the
anogenital genotypes, HPV-16, -18,- 31, -33, -35, -39, -45, -51, -52,
-56, -58, -59, -68, -73, and -82 were classified as high-risk group, because
they were clearly identified in patients with malignant cervical lesions16,24.
Uterine cervical cancer is the second most common type of cancer
among women worldwide, but in Latin America the prevalence rates are
about 4 fold higher than in USA and in other developed countries6.
Although available epidemiological information about this disease
is somehow scarce in Argentina, data show a significant variation in the
mortality rates for the different regions of the country; from 7 cases out
of 100,000 women in the metropolitan area of Buenos Aires city to 17-
22 cases out of 100,000 women in Northeast Argentina15. In spite of this
feature, few epidemiological studies were performed in this last region
related to HPV infection and they exclusively focused on a limited number
of genotypes, mainly –6, -11, -16 and –1830. For these reasons we
considered relevant to investigate the presence of other genotypes also
associated with cervical malignancy. The aim of this work was to evaluate
the presence of HPV genotypes infecting sexually active adult women
with cervical abnormalities, and correlate genotypes with the
cytohistological type of lesions.
MATERIALS AND METHODS
Subjects: All women self-referring for gynecological examination
at the Gynecology Service of “J.R.Vidal Hospital” in Corrientes city
and at a private gynecological clinic in Resistencia city, were enrolled in
a HPV study from August 2001 to August 2002. A routine gynecological
examination including colposcopy was completed, and exfoliated cervical
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cells were taken for PAP smear. Within the next 30 days, patients who
presented any cytohistological lesion, excluding inflammatory PAP
smears, were called again and asked for authorization for a new cervical
cell sampling to evaluate HPV infection. Upon this procedure, 53 women
were studied belonging to the following groups: 3 women with atypical
squamous cells of undetermined significance (ASCUS), 36 with low-
grade cervical intraepithelial lesions (L-SIL), 5 with high-grade cervical
intraepithelial lesions (H-SIL) and 9 with uterine cervical cancer in
different stages.
PCR for HPV detection: For viral analysis, cell samples were
collected by scraping the uterine ecto-endo cervix with a cytobrush. Cells
were washed in sterile buffered saline and the final cellular pellet was
kept at -70 ºC until DNA extraction.
DNA was obtained by treating the pellet with 400-700 µl of
homogenization solution (2% cetyltrimethylammonium bromide-CTAB,
1.4 M NaCl, 0.2% β-mercaptoethanol, 20 mM EDTA, 100 mM Tris-
HCl pH 5.0), extracted with phenol:chlorophorm:isoamyl alcohol
method, then precipitated with ethanol and resuspended in 50-100 µl
bidestilled sterile water. All samples were tested for quality and integrity
of DNA by PCR with the use of exon III from the human ß-actin gene
that produces a 289 bp amplimer. Samples negative for this primer were
considered unadequate and discarded.
PCR was performed in a reaction mixture of 100 µl containing 10 mM
Tris- HCl pH 8.3, 50 mM KCl, 2.5 mM Mg Cl2, 0.2 mM of each dNTP
(Promega Inc. – USA), 0.5 Units of Taq DNA polymerase (Promega
Inc. – USA), 0.5 mM of generic primers MY09 and MY11 (Cyber-Sin,
USA), and 5 µl of sample purified DNA. Each PCR was carried out in a
DNA thermal cycler (MJ Research Inc., PTC-150), with first denaturation
step at 94 ºC for 4 min and final extension step at 72 ºC for 5 min. DNA
amplification was performed during 35 cycles which included the
denaturation at 94 ºC for 60 s, the annealing at 52 ºC for 60 s, and the
primer extension at 72 ºC for 60 s. To avoid false negatives and false
positives a reagent control (no template DNA) and known HPV DNA
from infected HPV-16 CasKi cells were included in each amplification.
PCR product was electrophoresed on 3% agarose gel, stained with
ethidium bromide, and photographed under UV light.
Restriction digestion, RFLP analysis: Positive samples products
were digested as described by BERNARD et al.3, with 8-10 Units of
each one of the following enzymes: Bam HI, Dde I, Hae III, Hinf I, Pst
I, Rsa I and Sau3AI (Promega, USA). The digested products were
electrophoresed on 3% agarose gel, stained with ethidium bromide and
photographed under UV light. Restriction fragment length polymorphism
(RFLP) patterns were analyzed and compared with published data3.
RESULTS
Out of the 53 samples analyzed, 34 (64%) were positive for HPV-
DNA. Its distribution according to the type of cytohistological lesions is
referred in Table 1.
In regard to the genotypification, HPV infecting types could be
identified in 26/34 positive samples. From the 8 remaining samples, the
identification could not be resolved in 5 cases due to the fact that they
showed a very weak restriction pattern with a blurred image unable for
a distinct viral identification; 2 showed restriction maps which did not
correspond to none of the patterns described by BERNARD et al.3, and
the last one was a case of mixed infection with a very complicated
restriction pattern that could not be elucidated (Table 2).
Out of the 34 positive samples, 5 (14.7%) were multiple infection
cases produced by more than one viral genotype. In 4 of them final
genotyping could be successfully resolved by RFLP: HPV-58/45, HPV-
6/33, HPV-16/58, HPV-16/66, remaining one case undetermined.
DISCUSSION
Recent advances in molecular techniques allowed the use of highly
sensitive methodologies for the detection of HPV-DNA, such as filter in
situ hybridization (FISH), southern hybridization (SH), Hybrid Capturetm
(HC) and the polymerase chain reaction (PCR), being the latter one of
the most frequently employed2,7,13. However, these methodologies for
virological diagnosis do not replace classical gynecological exploration
techniques for cytohistological disturbances (PAP, colposcopy and
biopsies), but rather, they complement them22,25.
The high incidence of HPV infection previously reported in the Northern
region of Argentina20,30 is consistent with a high incidence of uterine cervix
cancer present in the area. In this work, only patients with cytohistological
Table 1
PCR for HPV-DNA in women with uterine cervical lesions
ASCUS L-SIL H-SIL Cervical Total
cancer
Positive 2 19 4 9 34
Negative 1 17 1 - 19
Total 3 36 5 9 53
Table 2
Distribution of HPV genotypes according to histopathological cervical
lesions, in 34 HPV-DNA positive samples
Genotype ASCUS L-SIL H-SIL Cervical Total
n = 3 n = 36 n = 5 cancer  n = 9 (%)
6 2 2 (5.9)
16 3 3 5 11 (32.3)
18 2 2 (5.9)
33 1 1 (2.9)
45 1 1 2 (5.9)
52 1 1 (2.9)
53 1 1 (2.9)
54 1 1 (2.9)
56 1 1 (2.9)
58 2 1 2 5 (14.7)
66 1 1 (2.9)
MM4 1 1 (2.9)
LVX100 1 1 (2.9)
Not identified* 1 3 1 5 (14.7)
Undetermined 2 1 3 (8.8)
* RFLP not done
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alterations and colposcopy compatible with HPV infection were studied.
As expected, we certainly found a high frequency of HPV infection,
particularly among H-SIL and cancer cases, while in the L-SIL group virus
DNA was found only in 52% of the cases. This percentage may be regarded
as low if compared with the findings of authors who referred infection rates
as high as 70%8. Nevertheless, in other reports the presence of viral DNA in
this type of patients is considered uncertain23. Our results could be directly
related to the number of cases analyzed and a better estimation could be
probably reached studying a greater number of L-SILs .
The PCR-RFLP technique employing MY generic primers allows
the recognition of more than 30 genital genotypes in a single amplification
reaction3. This is its major advantage in comparison to other
methodologies that use specific primers, but its disadvantage is just not
to be able to define certain cases of infection caused by multiple
genotypes, which frequently produce blurred restriction patterns1. In such
cases final identification may be achieved by PCR with subsequent Dot-
Blot hybridization, by PCR with specific primers, or by nucleotide
sequence analysis1,5,29.
In this work, RFLP analysis could not be performed in five positive
samples because genomic material did not amplify enough to obtain a
definite pattern with clear-cut bands. We suppose these cases may belong
to those whose initial viral genomic load stands on the limit of the
technique’s threshold14. Also, two samples showed patterns that could
not be associated with any of the genotypes described by the methodology
employed; therefore, it would be necessary to perform DNA sequence
analysis to assess if they correspond to intratypic variations, subtypes or
to novel genotypes19.
In agreement with the reports of other epidemiological surveys20,30,
HPV-16 was the most frequent genotype in our series, but HPV-58 was
in the second place instead of HPV-18, -31, -33 and –45 as in the most
of the series. However, geographical variations in the occurrence of the
HPV genotypes are well known and depends on the epidemiological
features of each region24.
The knowledge of the most prevalent HPV genotypes present in a
region with a high incidence of cervical cancer is relevant in order to
design an effective HPV nationwide vaccination program. In this way,
our research may be a contribution for a better knowledge of the problem
in an area without many data on HPV infection.
 We may conclude that in Northeastern Argentina, an important
number of high-risk HPV genotypes are circulating, and the results of
this study show that besides HPV-16 and HPV-18, other types like HPV-
58 are also frequent, as well as infections produced by more than one
genotype. Attention should be focussed on these circumstances since
they could be of local epidemiological significance.
RESUMEN
Genotipos de virus papiloma humano en mujeres con alteraciones
citológicas cervicales de un área con alta incidencia de cáncer
cervical
La relación entre la infección por los virus papiloma humanos (HPVs)
de alto riesgo y el cáncer de cuello de útero ha sido bien demostrada. En
el Nordeste de Argentina se observa una alta incidencia de esta patología
y en consecuencia se estima una alta prevalencia de infección por HPV.
A fin de identificar los genotipos de HPV presentes en el área, asociados
a casos de lesiones malignas y premalignas de cuello de útero, se
estudiaron 53 muestras ecto-endo cervicales de mujeres con alteraciones
citohistológicas residentes permanentes de las ciudades de Resistencia
y Corrientes. De las 53 pacientes estudiadas, 34 resultaron positivas para
HPV (64.2%), correspondiendo la mayor frecuencia a HPV-16 (32.3%),
seguido por HPV-58 (14.7%), HPV-6, -18 y –45 (5.9%), -33, -52, -53,
-54, -56, -66, -MM4 y –LVX100 (2.9%). Además, se encontraron 5
casos de infecciones mixtas causadas por mas de un genotipo, lo que
resulta de importancia ya que representan el 14.7% del total de los casos
positivos. Los resultados demuestran que, además de HPV-16 y –18 que
son los genotipos de alto riesgo de mayor prevalencia a nivel mundial,
otros como el HPV-45 y –58 y los casos de infecciones múltiples son
frecuentes en mujeres del nordeste argentino, lo que podría constituir un
rasgo epidemiológico de importancia regional y ser de utilidad en el
futuro en los programas de vacunación.
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